 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
24 News |  |
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment closed, Trial completion date, Trial primary completion date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Oct 31, 2022
P1/2, N=29, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Suspended --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Apr 2022 --> Apr 2024
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date, Trial primary completion date: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - Oct 28, 2022
P2a, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Suspended --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Apr 2022 --> Apr 2024 Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Jul 2024
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date, Trial primary completion date: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 (clinicaltrials.gov) - Feb 1, 2022
P2, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Jul 2024 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Sep 2022
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Journal: Mesenchymal stem cells in the treatment of severe COVID-19. (Pubmed Central) - Aug 17, 2021
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Sep 2022 No abstract available
- || Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P2 trial: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 (clinicaltrials.gov) - Mar 2, 2021
P2, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date, Trial primary completion date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Nov 2, 2020
P1/2, N=29, Suspended, Sponsor: Stemedica Cell Technologies, Inc.
No abstract available Trial completion date: May 2019 --> Dec 2022 | Trial primary completion date: Nov 2018 --> Apr 2022
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date, Trial primary completion date: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - Oct 29, 2020
P2a, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial completion date: May 2019 --> Dec 2022 | Trial primary completion date: Nov 2018 --> Apr 2022 Trial completion date: Jun 2020 --> Jun 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
- || Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion: A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure (clinicaltrials.gov) - Jan 7, 2020
P2a, N=23, Completed, Sponsor: CardioCell LLC
Trial completion date: Jun 2020 --> Jun 2023 | Trial primary completion date: Dec 2019 --> Dec 2022 Active, not recruiting --> Completed
- || Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment open: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - Apr 9, 2019
P2a, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- || Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) - Dec 3, 2018
P1/2, N=38, Completed, Sponsor: Stemedica Cell Technologies, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=38, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Dec 2018
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial completion date, Trial primary completion date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=29, Suspended, Sponsor: Stemedica Cell Technologies, Inc.
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Nov 2017 --> May 2019 | Trial primary completion date: Nov 2017 --> Nov 2018
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment closed, Trial completion date, Trial primary completion date: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - Apr 18, 2018
P2a, N=40, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial completion date: Nov 2017 --> May 2019 | Trial primary completion date: Nov 2017 --> Nov 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2019
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment change, Trial withdrawal: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - Apr 27, 2017
P2a, N=0, Withdrawn, Sponsor: Stemedica Cell Technologies, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Dec 2017 --> Dec 2019 N=50 --> 0 | Active, not recruiting --> Withdrawn
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial primary completion date: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) - Apr 26, 2017
P1/2, N=38, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
N=50 --> 0 | Active, not recruiting --> Withdrawn Trial primary completion date: Mar 2016 --> Sep 2017
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial suspension: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Oct 17, 2016
P1/2, N=29, Suspended, Sponsor: Stemedica Cell Technologies, Inc.
Trial primary completion date: Mar 2016 --> Sep 2017 Recruiting --> Suspended
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial primary completion date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Aug 2, 2016
P1/2, N=29, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Recruiting --> Suspended Trial primary completion date: Aug 2017 --> Nov 2017
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P2a trial: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease (clinicaltrials.gov) - Jul 14, 2016
P2a, N=40, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment closed: A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure (clinicaltrials.gov) - Apr 20, 2016
P2a, N=23, Active, not recruiting, Sponsor: CardioCell LLC
Trial primary completion date: Aug 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial primary completion date: A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure (clinicaltrials.gov) - Feb 24, 2016
P2a, N=20, Recruiting, Sponsor: CardioCell LLC
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2016 --> Apr 2017
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment closed, Trial primary completion date: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) - Dec 23, 2015
P1/2, N=38, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial primary completion date: Nov 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial primary completion date: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) - Sep 29, 2015
P1/2, N=35, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: May 2015 --> Dec 2015
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment open: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Aug 12, 2015
P1/2, N=29, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial primary completion date: May 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial initiation date, Trial primary completion date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=29, Not yet recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Not yet recruiting --> Recruiting Initiation date: Jun 2014 --> Aug 2015 | Trial primary completion date: Mar 2015 --> Aug 2017
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P2a trial: A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure (clinicaltrials.gov) - Jun 10, 2015
P2a, N=20, Recruiting, Sponsor: CardioCell LLC
- Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial primary completion date: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology (clinicaltrials.gov) - Mar 7, 2015
P2a, N=20, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Initiation date: Jun 2014 --> Aug 2015 | Trial primary completion date: Mar 2015 --> Aug 2017 Trial primary completion date: Nov 2014 --> Jun 2016
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment closed: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - Dec 7, 2014
P2a, N=50, Active, not recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Trial primary completion date: Nov 2014 --> Jun 2016 Recruiting --> Active, not recruiting
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment open: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology (clinicaltrials.gov) - Jun 23, 2014
P2a, N=20, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P2a trial: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology (clinicaltrials.gov) - Apr 8, 2014
P2a, N=20, Not yet recruiting, Sponsor: Stemedica Cell Technologies, Inc.
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Trial initiation date: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Apr 6, 2014
P1/2, N=29, Not yet recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Not yet recruiting --> Recruiting Initiation date: Mar 2013 --> Jun 2014
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment change: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - Apr 6, 2014
P2a, N=50, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
Initiation date: Mar 2013 --> Jun 2014 N=40 --> 50
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
Enrollment open: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - Jun 16, 2013
P2a, N=50, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
N=40 --> 50 Not yet recruiting --> Recruiting
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P2a trial: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - Jan 16, 2013
P2a, N=50, Recruiting, Sponsor: Stemedica Cell Technologies, Inc.
- | Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
New P1/2 trial: Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging (clinicaltrials.gov) - Jan 16, 2013
P1/2, N=29, Not yet recruiting, Sponsor: Stemedica Cell Technologies, Inc.